Skip to content ↓

Miklos Porkolab receives Hannes Alfvén Prize

Professor cited for contributions to fusion energy development and the physics of plasma waves
Miklos Porkolab
Caption:
Miklos Porkolab
Credits:
Photo: Paul Rivenberg

Professor Miklos Porkolab, director of the Plasma Science and Fusion Center at MIT and professor in the MIT's Department of Physics, received the 2013 Hannes Alfvén Prize at a ceremony held in Espoo (Helsinki), Finland on July 1.

The honor, given annually by the European Physical Society (EPS) during their Conference on Plasma Physics, recognizes outstanding work in the field of plasma science and fusion research.

Porkolab was cited “for his seminal contributions to the physics of plasma waves and his key role in the development of fusion energy." Noting additional areas of his research, including the areas of magnetic reconnection, laser-plasma interaction and inertial confinement fusion, the citation concludes: “With such a broad scientific expertise in plasma physics, unique contributions to first-rate theories, exciting and novel experiments and development of innovative diagnostic techniques, as well as with a great devotion to science education and service, Miklos Porkolab has a strong impact on fusion energy research worldwide.”

Related Links

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story